CamAPS Liberty
CamDiab / mylife Diabetes Care
A real reduction in meal tasks, with important evidence limits.
What it is
An optional fully closed-loop mode inside CamAPS FX, launched with myLoop/YpsoPump in Germany, Austria, Switzerland and Luxembourg on 1 September 2026. It removes routine meal boluses and carbohydrate counting for people with T1D aged 13 and older, excluding pregnancy. Small predecessor studies improved time in range over nonautomated pump plus CGM; they did not establish superiority over modern hybrid closed loop.
Editorial review: . What was checked and what remains uncertain.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Time in range: Editorial estimate: Predecessor CamAPS HX studies enrolled people with above-target HbA1c. Adult TIR was about 50% and adolescent TIR 45.2%, improved versus nonautomated pump/CGM; cross-study ranking against optimized hybrid AID is unreliable.[4]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Confirmed launch in Germany, Austria, Switzerland and Luxembourg; Italy28 October is a company target. Broader regional availability should not be inferred.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the record-specific review limits for gaps in evidence, source access or availability checks.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 55 × 20 + 70 × 20 + 93 × 10 + 50 × 5 + 50 × 5 + 65 × 5 + 75 × 5 + 42 × 10 + 78 × 20 = 6610; divide by total weight 100. Unrounded weighted result: 66.1.
Editorial estimate: Predecessor CamAPS HX studies enrolled people with above-target HbA1c. Adult TIR was about 50% and adolescent TIR 45.2%, improved versus nonautomated pump/CGM; cross-study ranking against optimized hybrid AID is unreliable.[4]
Editorial estimate: The adolescent crossover study found similar time below range between interventions. Small samples and short follow-up cannot establish rare-event safety or a benefit over hybrid AID.[4]
Editorial estimate: Routine meal and snack boluses are not required with Liberty active; the user can switch modes and retain manual boluses. Sensor, pump, infusion-set care and supervision remain necessary.[2]
Editorial estimate: The adolescent predecessor study reduced mean glucose versus nonautomated pump/CGM, but time above range remained substantial. No independent large commercial Liberty dataset is established here.[4]
Editorial estimate: The adolescent study did not show lower glucose SD, and glucose CV was higher during fully closed loop; eliminating meal input does not imply normal glucose variability.[4]
Editorial estimate: Ease-off and other CamAPS features remain available. This does not establish reliable handling of every unannounced exercise episode.[2]
Editorial estimate: Liberty can be toggled; Boost, Ease-off, Add meal and manual boluses remain available, within the system’s safety controls.[2]
Editorial estimate: Commercial launch confirmed in four named European markets; Italy targeted 28 October. Regional rollout, compatible hardware and local access remain restrictions. Not a verified US FDA fully closed-loop indication.[1]
Editorial estimate: Removing routine meal calculations may reduce burden, but the system still uses a tubed YpsoPump, phone and CGM. Manufacturer survey feedback is not a randomized outcome.[2]
AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.
Editor’s take
Liberty changes the practical map: insulin-only fully closed loop is now commercially available in selected markets. Its strongest established distinction is reduced meal input. The predecessor trials enrolled people whose HbA1c was above target and compared against nonautomated pump therapy, so they do not show that switching from successful hybrid AID preserves or improves glucose outcomes. The adult/pediatric and pregnancy labels must be read separately.
The full picture
CamAPS Liberty is a selectable mode within CamAPS FX. With the mode active, routine carbohydrate counting and meal/snack boluses are not required. Manual boluses and existing Boost, Ease-off and Add meal functions remain available. It still requires compatible insulin-delivery hardware, a sensor, a phone, device maintenance and attention to alerts.1
Who can use it. The CE-marked mode is for T1D from age 13 and is not intended for pregnancy. Those restrictions differ from the broader standard CamAPS FX indication. The September launch names myLoop/YpsoPump in Germany, Austria, Switzerland and Luxembourg. Italy is targeted for 28 October; future-country plans are not present availability.2
What the evidence can show. The manufacturer links Liberty to the CamAPS HX research algorithm. An eight-week adult crossover study in people with above-target HbA1c reported approximately 50% time in range versus 36% with nonautomated pump plus CGM.3 In 24 adolescents aged 13–19, two eight-week periods produced 45.2% versus 32.3% time in range (difference 12.9 percentage points), with similar time below range. Mean glucose improved, but glucose variability did not consistently improve.4 These were selected high-HbA1c populations; neither study compared Liberty against current hybrid AID. The historical study configuration and commercial feature should not be assumed identical in every setting.
The manufacturer’s 83% recommendation statistic came from 41 survey respondents among 59 people completing four weeks. It measures early user feedback, not glycemic efficacy or independent safety.1 No score here is a measured probability or a head-to-head product result.
References
-
mylife Diabetes Care. CamAPS Liberty information. https://www.mylife-diabetescare.com/en/myloop/camaps-liberty ↩ ↩2
-
CamDiab, 1 September 2026. https://camdiab.com/press-releases/liberty-launch ↩
-
Boughton et al. Diabetes Care2023. https://pubmed.ncbi.nlm.nih.gov/37616583/ ↩
-
Kadiyala et al. Diabetes Technology & Therapeutics2025. https://journals.sagepub.com/doi/10.1089/dia.2025.0062 ↩
What's next for this
- →Italy launch · 28 October 2026 company target
- →Independent post-launch effectiveness, safety and direct comparisons with hybrid AID · No verified readout date
Sources
- [1]CamDiab and mylife announce CamAPS Liberty commercial launch · manufacturer
- [2]CamAPS Liberty product information and restrictions · manufacturer
- [3]Boughton et al. Fully closed-loop versus pump/CGM in adults with T1D · peer-reviewed
- [4]Kadiyala et al. Fully closed-loop versus pump/CGM in adolescents with T1D · peer-reviewed